SLRX RSI Chart
Last 7 days
2%
Last 30 days
4.1%
Last 90 days
-7.3%
Trailing 12 Months
-70%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2021 | 5.4M | 4.7M | 3.3M | 1.8M |
2020 | 3.9M | 4.3M | 4.8M | 5.2M |
2019 | 1.5M | 2.2M | 2.6M | 3.5M |
2018 | 1.2M | 1.1M | 1.2M | 1.1M |
2017 | 1.3M | 1.5M | 1.3M | 1.3M |
2016 | 171.8K | 268.3K | 852.7K | 1.1M |
2015 | 22.5K | 36.0K | 43.8K | 72.0K |
2014 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 13, 2023 | rosenblum mark j | acquired | - | - | 6,432 | exec vp finance, cfo |
Feb 13, 2023 | arthur david j. | acquired | - | - | 14,300 | chief executive officer |
Jan 03, 2023 | arthur david j. | acquired | - | - | 20,000 | chief executive officer |
Jan 03, 2023 | mccreedy bruce j jr. | acquired | - | - | 1,440 | - |
Jan 03, 2023 | mcvicar william k. | acquired | - | - | 1,440 | - |
Jan 03, 2023 | lammers paul | acquired | - | - | 1,440 | - |
Jan 03, 2023 | lieber jonathan i | acquired | - | - | 1,440 | - |
Jan 03, 2023 | rosenblum mark j | acquired | - | - | 8,000 | exec vp finance, cfo |
Jan 03, 2023 | hanish arnold c | acquired | - | - | 1,440 | - |
Jan 03, 2023 | burleson tess | acquired | - | - | 1,440 | - |
Which funds bought or sold SLRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 2.1 | 82.00 | 9,466 | -% |
Feb 15, 2024 | HORIZON KINETICS ASSET MANAGEMENT LLC | reduced | -4.03 | -1,105 | 20,211 | -% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -50.00 | -11.00 | 10.00 | -% |
Feb 14, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 8,445 | 8,445 | -% |
Feb 14, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 122 | 10,470 | 19,536 | -% |
Feb 14, 2024 | CITADEL ADVISORS LLC | new | - | 15,670 | 15,670 | -% |
Feb 13, 2024 | MORGAN STANLEY | reduced | -72.73 | -106 | 39.00 | -% |
Feb 13, 2024 | FMR LLC | reduced | -32.65 | -11.00 | 21.00 | -% |
Feb 13, 2024 | ARMISTICE CAPITAL, LLC | reduced | -60.89 | -90,828 | 57,200 | -% |
Unveiling Salarius Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Salarius Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 47.9B | 6.8B | -8.03 | 7 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.3B | 2.0B | -58.02 | 9.62 | ||||
BMRN | 15.7B | 2.5B | 76.24 | 6.34 | ||||
INCY | 12.1B | 3.8B | 16.19 | 3.2 | ||||
MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -10.82 | 14.42 | ||||
BBIO | 5.2B | 107.9M | -9.53 | 48.09 | ||||
AXSM | 3.5B | 270.6M | -14.81 | 13.09 | ||||
ARWR | 3.0B | 240.7M | -10.2 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.79 | 3.86 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | 24.31 | 4.36 | ||||
NVAX | 687.2M | 983.7M | -1.26 | 0.7 | ||||
CRBP | 408.0M | 881.7K | -9.15 | 466.16 | ||||
INO | 282.8M | 4.9M | -2.09 | 58.11 | ||||
IBIO | 6.9M | 2.1M | -0.25 | 2.14 |
Salarius Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 |
Revenue | - | - | - | 571,387 | 1,268,829 | 1,478,922 | 1,378,239 | 1,243,310 | 1,132,830 | 1,038,693 | 874,949 | 895,778 | 655,635 | 163,067 | 469,051 | 245,502 | 178,582 | 282,828 | 413,601 | 335,523 | 242,547 | 298,904 |
Operating Expenses | 10.6% | 4,144,856 | 3,746,660 | 3,688,207 | 3,073,424 | 3,236,250 | 3,136,744 | 3,144,264 | 3,502,388 | 3,098,719 | 4,635,114 | 1,807,880 | 2,188,419 | 2,184,206 | 782,565 | 9,349,183 | 8,461,402 | - | - | - | - | - |
S&GA Expenses | -16.3% | 1,449,223 | 1,730,730 | 1,591,905 | 1,332,769 | 1,212,772 | 1,333,062 | 1,700,942 | 1,859,017 | 1,760,750 | 3,494,205 | 967,736 | 1,488,490 | 1,921,513 | 428,958 | 2,994,649 | 3,697,287 | - | - | - | - | - |
R&D Expenses | 33.7% | 2,695,633 | 2,015,930 | 2,096,302 | 1,740,655 | 2,023,478 | 1,803,682 | 1,443,322 | 1,643,371 | 1,337,969 | 1,140,909 | 840,144 | 699,929 | 187,759 | 353,607 | 6,174,589 | 4,680,181 | - | - | - | - | - |
EBITDA Margin | -80.4% | -20.24 | -11.22 | -7.93 | -6.94 | -7.12 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | 294 | 1,174 | 2,048 | 2,340 | 1,214 | 3,061 | 2,138 | 6,867 | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | -80.4% | -20.25 | -11.23 | -7.93 | -6.94 | -7.12 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -9.8% | -4,104,873 | -3,737,100 | -3,074,369 | -1,851,896 | -1,767,548 | -1,716,632 | -1,784,258 | -2,083,816 | -1,882,821 | -2,627,721 | -903,645 | -1,522,076 | -2,008,745 | -307,450 | 111,233 | -381,549 | - | - | - | - | - |
Net Income Margin | -120.8% | -6.94 | -3.14 | -1.79 | -1.33 | -1.40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -72.0% | -2,720,603 | -1,582,024 | -3,174,780 | -2,722,790 | -1,373,484 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -21.6% | 6,587 | 8,404 | 12,055 | 10,055 | 14,651 | 19,723 | 33,654 | 35,508 | 40,834 | 44,263 | 47,405 | 50,768 | 24,932 | 23,063 | 18,562 | 20,065 | 13,894 | 14,458 | 7,137 | 8,184 | 6,614 |
Current Assets | -21.7% | 6,520 | 8,324 | 11,956 | 9,940 | 14,520 | 17,966 | 23,015 | 24,856 | 30,164 | 35,184 | 38,307 | 41,651 | 15,797 | 13,919 | 9,397 | 10,884 | 4,695 | 5,239 | 7,109 | 8,146 | 6,381 |
Cash Equivalents | -22.2% | 5,900 | 7,581 | 11,541 | 9,274 | 12,106 | 16,820 | 22,647 | 24,194 | 29,214 | 31,904 | 33,079 | 36,612 | 11,119 | 9,558 | 7,223 | 9,647 | 3,739 | 4,000 | 4,138 | 5,771 | 6,132 |
Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 131 | 165 | 187 |
Net PPE | - | - | - | - | - | - | - | - | 4.00 | 8.00 | 12.00 | 15.00 | 19.00 | 23.00 | 16.00 | 19.00 | 22.00 | 25.00 | 28.00 | 28.00 | 38.00 | 38.00 |
Goodwill | - | - | - | - | - | - | - | 8,866 | 8,866 | 8,866 | 8,866 | 8,866 | 8,866 | 8,866 | 8,866 | 8,866 | 8,866 | 8,866 | 8,866 | - | - | - |
Liabilities | -44.0% | 1,299 | 2,321 | 3,641 | 4,496 | 4,266 | 3,110 | 2,770 | 2,092 | 2,111 | 1,612 | 1,554 | 1,989 | 2,773 | 2,457 | 1,707 | 2,063 | 3,314 | 4,721 | 1,036 | 911 | 7,885 |
Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,036 | 911 | 1,107 |
Shareholder's Equity | -13.1% | 5,287 | 6,084 | 8,414 | 5,559 | 10,385 | 16,613 | 30,884 | 33,416 | 38,723 | 42,651 | 45,851 | 48,778 | 22,159 | 20,606 | 16,855 | 18,003 | 10,581 | 9,737 | 733 | 1,730 | 9,283 |
Retained Earnings | -1.2% | -76,347 | -75,466 | -73,023 | -69,145 | -63,805 | -57,434 | -43,024 | -38,306 | -32,197 | -28,092 | -24,355 | -21,280 | -19,428 | -17,661 | -15,944 | -14,160 | -12,076 | -10,193 | -136,576 | -135,191 | -5,140 |
Additional Paid-In Capital | 0.1% | 81,635 | 81,549 | 81,437 | 74,705 | 74,190 | 74,047 | 73,903 | 71,717 | 70,920 | 70,739 | 70,202 | 70,054 | 41,586 | 38,265 | 32,798 | 32,162 | 22,657 | 19,927 | 142,676 | 142,463 | 3,869 |
Shares Outstanding | 0% | 3,938 | 3,938 | 3,352 | 2,468 | 2,256 | 2,081 | 1,996 | 1,850 | 1,810 | 1,792 | 1,506 | 1,222 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 4,921 | - | - | - | 11,654 | - | - | - | 47,291 | - | - | - | 19,158 | 9,204 | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 59.7% | -1,511 | -3,749 | -4,416 | -3,169 | -4,713 | -5,741 | -3,619 | -3,520 | -2,720 | -1,582 | -3,174 | -2,722 | -1,373 | -2,753 | -2,476 | -3,708 | -2,636 | -5,541 | -1,533 | -1,868 | 388 |
Share Based Compensation | -24.2% | 85.00 | 113 | 123 | 203 | 146 | 138 | 200 | 314 | 146 | 130 | 147 | 135 | 170 | 78.00 | 33.00 | 38.00 | 172 | 538 | 6.00 | 35.00 | -21.82 |
Cashflow From Investing | - | - | - | - | - | - | - | - | -1,500 | - | - | - | - | -2.60 | - | - | - | - | 5,608 | - | - | - |
Cashflow From Financing | 20.0% | -169 | -211 | 6,684 | 337 | 1* | -85.69 | 2,073 | - | 31.00 | 406 | -358 | 28,216 | 2,937 | 5,088 | 53.00 | 9,616 | 2,376 | -204 | -99.76 | 1,508 | -306 |
Dividend Payments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.00 | - | - | - |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 7,173,747 | $ 15,836,828 |
General and administrative | 5,721,197 | 7,138,403 |
Loss on impairment of goodwill | 0 | 8,865,909 |
Total operating expenses | 12,894,944 | 31,841,140 |
Loss before other income (expense) | (12,894,944) | (31,841,140) |
Change in fair value of warrant liability | 0 | 14,454 |
Interest income | 352,251 | 218,730 |
Net loss | (12,542,693) | (31,607,956) |
Loss attributable to common stockholders | $ (12,542,693) | $ (31,607,956) |
Loss per common share, basic (in dollars per share) | $ (3.84) | $ (14.88) |
Loss per common share, diluted (in dollars per share) | (3.84) | (14.88) |
Total net loss per share (in dollars per share) | $ (3.84) | $ (14.88) |
Weighted average number of shares outstanding, basic (in shares) | 3,264,620 | 2,124,511 |
Weighted average number of shares outstanding, diluted (in shares) | 3,264,620 | 2,124,511 |
CONSOLIDATED BALANCE SHEETS - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,899,910 | $ 12,106,435 |
Grants receivable from CPRIT | 0 | 1,610,490 |
Prepaid expenses and other current assets | 619,763 | 803,373 |
Total current assets | 6,519,673 | 14,520,298 |
Other assets | 66,850 | 130,501 |
Total assets | 6,586,523 | 14,650,799 |
Current liabilities: | ||
Accounts payable | 602,853 | 2,858,330 |
Accrued expenses and other current liabilities | 406,745 | 1,407,861 |
Notes payable | 289,643 | 0 |
Total liabilities | 1,299,241 | 4,266,191 |
Commitments and contingencies (NOTE 5) | ||
Stockholders' equity (deficit): | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued or outstanding | 0 | 0 |
Common stock, $0.0001 par value; 100,000,000 shares authorized; 3,938,433 and 2,255,899 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 393 | 225 |
Additional paid-in capital | 81,634,730 | 74,189,531 |
Accumulated deficit | (76,347,841) | (63,805,148) |
Total stockholders' equity | 5,287,282 | 10,384,608 |
Total liabilities and stockholders' equity | $ 6,586,523 | $ 14,650,799 |